Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: A potential marker of irreversible thyroid dysfunction?

Thyroid

Volumn 20, Issue 3, 2010, Pages 317-322

  Rogiers, Aljosja ^a   Wolter, Pascal ^a   De Beeck, Katya Op ^a   Thijs, Marleen ^a   Decallonne, Brigitte ^a   Schöffski, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LEVOTHYROXINE; LIOTHYRONINE; SORAFENIB; SUNITINIB; THIAMAZOLE; THYROGLOBULIN; THYROTROPIN; THYROXINE;

AGED; ARTICLE; ASPIRATION BIOPSY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPERTHYROXINEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SIDE EFFECT; THYROID DISEASE; THYROID FUNCTION TEST; THYROID WEIGHT; THYROIDITIS; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FATAL OUTCOME; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MALE; ORGAN SIZE; PYRROLES; THYROID GLAND;

EID: 77649291310     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0125     Document Type: Article

References (34)

1. Chow LQ, Eckhardt SG 2007 Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896.
2. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic=pharmacodynamic relationship. Clin Cancer Res 9:327-337.
3. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24.
4. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338.
5. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ 2007 Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799.
6. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD 2006 Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816.
7. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV 2008 Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656.
8. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454.
9. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664.
10. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355.
11. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83.
12. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyro-sine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534.
13. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576.
14. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM 2006 Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290:H509-H511.
15. Clement P, Wolter P, Stefan C, Decallonne B, Dumez H, Wildiers H, Schöffski P 2008 Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. J Clin Oncol (Meeting abstracts) 26:16145.
16. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579.
17. Sato K, Miyakawa M, Onoda N, Demura H, Yamashita T, Miura M, Kasajima T, Yamazaki K, Obara T 1997 Increased concentration of vascular endothelial growth factor=vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. J Clin Endocrinol Metab 82:1968-1973.
18. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ 1998 Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 157:5-12.
19. Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T, Shibuya M 1999 Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol 30:891-897.
20. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A, Leclére J 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161:41-49.
21. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, Leclère J, Duprez A, Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656-658.
22. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL 2000 The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10:349-357.
23. Ramsden JD 2000 Angiogenesis in the thyroid gland. J Endocrinol 166:475-480.
24. Nagura S, Katoh R, Miyagi E, Shibuya M, Kawaoi A 2001 Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol 32: 10-17.
25. De la Torre NG, Buley I, Wass JA, Turner HE 2006 Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 13:931-944.
26. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S 2007 Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 88:271-277.
27. Wollman SH, Herveg JP, Zeligs JD, Ericson LE 1978 Blood capillary enlargement during the development of thyroid hyperplasia in the rat. Endocrinology 103:2306-2314.
28. Liu Y, Wang D, Redetzke RA, Sherer BA, Gerdes AM 2009 Thyroid hormone analog 3,5-diiodothyropropionic acid promotes healthy vasculature in the adult myocardium independent of thyroid effects on cardiac function. Am J Physiol Heart Circ Physiol 296:H1551-H1557.
29. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ 2004 Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94:1500-1506.
30. Davis PJ, Leonard JL, Davis FB 2008 Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 29:211-218.
31. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 17:1147-1149.
32. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672.
33. Alexandrescu DT, Popoveniuc G, Farzanmehr H, Dasanu CA, Dawson N, Wartofsky L 2008 Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18:809-812.
34. Salem AK, Fenton MS, Marion KM, Hershman JM 2008 Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631-635.